Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 48, Issue 2, 2013, Pages 249-252

  Crocchiolo, R ^a   Castagna, L ^a,b   Furst S ^a   El Cheikh, J ^a   Faucher, C ^a   Oudin, C ^a   Granata, A ^a   Bouabdallah, R ^a   Coso, D ^a   Chabannon, C ^a,c,d   Balzarotti, M ^b   Santoro, A ^b   Blaise, D ^a,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c INSERM   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

allogeneic; autologous; non Hodgkin's lymphoma; SCT; tandem

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; RITUXIMAB; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD DONOR; CANCER RECURRENCE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FEASIBILITY STUDY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HIGH RISK PATIENT; HLA MATCHING; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PLASMOCYTOID LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; REVIEW; SALVAGE THERAPY; SIBLING; UNRELATED DONORS;

ADULT; AGED; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84873461953     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.116     Document Type: Review

References (29)

1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 7: 1540-1545
2. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-4190
3. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: Pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316-2323
4. Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A et al. Favorable longterm survival after reduced-intensity allogeneic transplantation for multiplerelapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 426-432
5. Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: Report of the Socie'té Française de Greffe de Moelle et de The'rapie Cellulaire. Biol Blood Marrow Transplant 2010; 16: 78-85
6. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530-5536
7. Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: A report of the International Bone Marrow Transplant Registry. Blood 2004; 104: 3797-3803
8. van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R et al. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: Long-term outcomes. Biol Blood Marrow Transplant 2009; 15: 554-563
9. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non- Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493-1498
10. Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998; 16: 3264-3269
11. Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D et al. Ageadjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989-1996
12. Blaise D, Farnault L, Faucher C, Marchetti N, Fürst S, El Cheikh J et al. Reducedintensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. Exp Hematol 2010; 38: 1241-1250
13. Crocchiolo R, Fürst S, Esterni B, Castagna L, El-Cheikh J, Faucher C et al. Two days of ATG in the conditioning regimen is associated with a reduced incidence of both acute and chronic GvHD without increasing relapse in RIC transplant for haematological disease. Bone Marrow Transplant 2011; 46(Suppl 1s, abstract 288).
14. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
15. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706
16. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304
17. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217
18. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956
19. Cox DR. Regression models and life tables. J Royal Stat Soc 1972; 34: 187-220
20. Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918-3924
21. Gutman JA, Bearman SI, Nieto Y, Sweetenham JW, Jones RB, Shpall EJ et al. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: A feasibility study. Bone Marrow Transplant 2005; 36: 443-451
22. Buser AS, Heim D, Bucher C, Tichelli A, Gratwohl A, Passweg Jr. High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma. Bone Marrow Transplant 2004; 33: 1011-1014
23. Buser AS, Stern M, Bucher C, Arber C, Heim D, Halter J et al. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: A comparison of delayed versus immediate transplantation. Bone Marrow Transplant 2007; 39: 335-340
24. Cohen S, Kiss T, Lachance S, Roy DC, Sauvageau G, Busque L et al. Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. Biol Blood Marrow Transplant 2011 (e-pub ahead of print 7 December 2011).
25. Tiercy JM, Nicoloso G, Passweg J, Schanz U, Seger R, Chalandon Y et al. The probability of identifying a 10/10 HLA allele-matched unrelated donor is highly predictable. Bone Marrow Transplant 2007; 40: 515-522
26. Tiercy JM, Bujan-Lose M, Chapuis B, Gratwohl A, Gmür J, Seger R et al. Bone marrow transplantation with unrelated donors: What is the probability of identifying an HLA-A/B/Cw/DRB1/B3/B5/DQB1-matched donor? Bone Marrow Transplant 2000; 26: 437-441
27. Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: A study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 256-263
28. Wang HX, Yan HM, Liu J, Duan LN, Wang ZD, Zhu L et al. Haploidentical hematopoietic stem-cell transplantation for non-Hodgkin lymphoma with bone marrow involvement. Leuk Lymphoma 2009; 50: 1488-1493
29. Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: Posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 2009; 113: 4771-4779